(Q50303533)

2 March 2018

review article

1 reference

title

[Autistic disorder: current psychopharmacological treatments and areas of interest for future developments]. (English)

1 reference

2 March 2018

0 references

3

1 reference

2 March 2018

author name string

Roumen Nikolov

series ordinal

1

1 reference

2 March 2018

Jacob Jonker

series ordinal

2

1 reference

2 March 2018

language of work or name

non-English

0 references

publication date

1 May 2006

1 reference

2 March 2018

Brazilian Journal of Psychiatry

published in

1 reference

2 March 2018

volume

28 Suppl 1

1 reference

2 March 2018

page(s)

S39-46

1 reference

2 March 2018

cites work

The prevalence of autism

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

A placebo-controlled trial of risperidone in Tourette syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

The role of serotonin in antipsychotic drug action

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

Risperidone in children with autism and serious behavioral problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

Radioreceptor binding profile of the atypical antipsychotic olanzapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

Adverse effects of clomipramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

Olanzapine versus haloperidol in children with autistic disorder: an open pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

Olanzapine-induced diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

Open-label quetiapine in the treatment of children and adolescents with autistic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

Case series: use of ziprasidone for maladaptive symptoms in youths with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

Partial dopamine agonists in the treatment of psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

Aripiprazole for maladaptive behavior in pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

Clomipramine ameliorates adventitious movements and compulsions in prepubertal boys with autistic disorder and severe mental retardation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

Clomipramine in adults with pervasive developmental disorders: a prospective open-label investigation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

Clomipramine treatment of stereotypic behaviors and self-injury in patients with developmental disabilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

A pilot study of clomipramine in young autistic children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

Fluoxetine Treatment of Children and Adults with Autistic Disorder and Mental Retardation

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

Paroxetine for self-injurious behavior.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

21 January 2018

Paroxetine in autism.

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

Use of citalopram in pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

Lithium responsive manic-like symptoms in two individuals with autism and mental retardation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

Brief report: A synopsis of an open-trial of naltrexone treatment of autism with four children

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

Naltrexone in autistic children: an acute open dose range tolerance trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

Naltrexone in autistic children: behavioral symptoms and attentional learning

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

Naltrexone and communication skills in young children with autism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

Autism and the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

Brief report: a pilot open clinical trial of intravenous immunoglobulin in childhood autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

Short-term benefit from oral vancomycin treatment of regressive-onset autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

Hypothesis: is infantile autism a hypoglutamatergic disorder? Relevance of glutamate - serotonin interactions for pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of D-cycloserine

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

A pilot study of D-cycloserine in subjects with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006000500006

10.1590/S1516-44462006000500006

21 January 2018

Identifiers

DOI

1 reference

2 March 2018

1 reference

2 March 2018